Global Therapy Monitors
The foundation for better decision-making
What's the uptake of your brand? How big is your market? What's the usage profile of your competitors? The answers to these and many more key business questions are held by Global Therapy Monitors.
Syndicated studies run by therapy area and methodology experts, Global Therapy Monitors provide prescribing data and expert analysis across 17 disease areas and 23 markets worldwide.
How can Global Therapy Monitors help you?
Our gold standard data has extensive applications:
- Understand market size and competitive structure
- Track competitor product use (patient types, etc.)
- Gauge new product uptake / penetration
- Provide forecast inputs for potential products
- Assess treatment outcomes by regimen
- Compare doctor perceptions versus actual prescribing behaviour
Our client service package includes a full database and training, an ad hoc query service and a personalised presentation or customised tables.
What disease areas do we cover?
- Oncology (for full details visit Global Oncology Monitor)
- Antiviral (HIV, Hepatitis B and C)
- Autoimmune (Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease, PsA, AS)
- Metabolics (Diabetes)
- CNS (Bipolar, Schizophrenia)
- Antifungal
Why Synovate's Global Therapy Monitors?
Better information, better delivered, by better people.
Our dedicated Therapy Monitor teams have expert knowledge across indications and markets, enabling them to meet and anticipate your information needs.
To this, we add proprietary analytics to drive maximum understanding, an online methodology in a unique breadth of indications and proprietary dashboards and user-friendly software for ease of use.
Additional services including patient flow models, country opportunity market trackers, patient, nurse and Key Opinion Leader studies.
Synovate Healthcare SCOPE
Complimenting Therapy Monitors, Scope provides a deep dive into specific prescribing segments within particular therapeutic classes e.g. the dynamic segment. SCOPE is currently launched in Europe and US for HIV and RA, with expansion planned.